Velit Biopharma, founded in 2018 and headquartered in Milan, specializes in the development and registration of “hard-to-make” medicines. Through strategic partnerships with pharmaceutical companies and distributors worldwide, Velit ensures these medicines reach patients globally. With over 100 active partnership agreements spanning Europe, Asia, and the Middle East, Velit boasts a diverse portfolio of more than 50 pharmaceutical products. The company’s strong pipeline includes ongoing developments in gastroenterology, dermatology, and women’s health.

Kelso Pharma, established in 2020 and based in Edinburgh (Scotland), is dedicated to introducing innovative and value-added specialty medicines to the European healthcare markets. Supported by Apposite Capital, a leading London-based private equity firm specializing in healthcare SME businesses, Kelso Pharma is positioned for impact and growth.

Cross Border, leveraging its specialized Healthcare Team, served as the financial advisor to Velit Biopharma’s owners. This comprehensive support included aiding in the search for suitable counterparts, drafting meticulous investor documentation, and facilitating the negotiation and structuring processes of the operation. Throughout the execution and due diligence phases, Cross Border actively guided Velit, contributing to the successful conclusion of the transaction. Beyond this, Cross Border played a pivotal role in fostering further international success by actively assisting in the development of a robust global specialty pharmaceutical business. The owners of Velit will participate to the upside of the value creation of the combined entities.